お知らせ • Jan 28
Oryzon Genomics S.A. Announces Board Elections, Effective February 28, 2025
Oryzon Genomics, S.A. announced significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28, 2025. Four new members will be added to the Board: Dr. Konstantinos Alataris, Dr. Pierre Beaurang, Dr. Montserrat Vendrell, and Luis Sánchez Quintana. At the same time, in accordance with Spanish law, several independent directors are approaching the maximum tenure of 12 years. Consequently, the independent directors Ramón Adell, Isabel Aguilera and Antonio Fornieles will conclude their terms. Additionally, Mr. Josep Ma Echarri and Dr. Tamara Maes have announced their intention to step down. Mr. Echarri cited the accumulation of responsibilities across various public company boards as the reason for his decision, while Dr. Maes stated personal reasons not to stand for reelection. Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting. Dr. Konstantinos Alataris is an accomplished entrepreneur with over 30 years of experience in the United States. He specializes in scaling innovative medical technology companies and successfully commercializing novel therapeutics. With a strong background as a founder, CEO, investor, and board member in the medical device industry, Dr. Alataris brings invaluable expertise to his endeavors. Notable positions in his career include serving as the Founder, President, and CEO of Nevro Corp, as well as the CEO and Co-Founder of Nesos and the President and CEO of Zosano Pharma. Additionally, Dr. Alataris has chaired the scientific advisory board of iota Biosciences, which was acquired by Astellas Pharma. He has worked in various fields, including autoimmune, neurosurgical, neurological, neuropsychiatric, orthopedic, and cardiac disorders, both in operational roles and as a board member. Dr. Alataris holds a B.A. in Electrical and Electronics Engineering by the University of Athens, a PhD in Bioengineering & Biomedical Engineering by the University of Southern California and MBA in Finance by the University of Southern California. Dr. Pierre Beaurang brings over 25 years of experience in biotechnology, with a focus on corporate strategy, business development, oncology, immunology, and neurology. Most recently, Dr. Beaurang served as CEO of Nitrase Therapeutics, a private biotechnology company specializing in a novel class of enzymes associated with neurodegenerative disorders and cancer. Previously, he held the position of Chief Business Officer at Nurix Therapeutics, where he played a pivotal role in scaling the company into a publicly traded, clinical-stage enterprise. During his time at Nurix, Dr. Beaurang led the establishment of transformative partnerships with global pharmaceutical companies and was an integral part of the leadership team driving the company’s successful IPO. Dr. Beaurang was also a founding member of Five Prime Therapeutics (later acquired by Amgen), an oncology and immunology biologics company. At Five Prime, he secured several major platform and product collaborations with pharmaceutical companies and licensed the company’s lead asset, which ultimately resulted in its acquisition for $1.9 billion in 2021. Dr. Beaurang holds a B.A. in Biology and an M.A. in Biotechnology from Boston University, as well as a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. Luis Sánchez Quintana is a former Partner at PwC, bringing over 33 years of professional experience, including 17 years as a Partner. During his tenure, he held the prestigious role of Global Head of the Pharma and Life Sciences Sector, where he provided strategic guidance to numerous leading companies. Mr. Sánchez Quintana served as Audit Partner for Laboratorios Rovi, supporting its growth trajectory and eventual IPO, as well as for other listed companies in the Spanish pharmaceutical sector, including Pharmamar and Faes. His extensive portfolio also includes serving as Audit Partner for key subsidiaries of multinational groups such as MSD, BMS, AstraZeneca, Roche, Laboratorios Indas, Farmalíder, Teva, GSK, Janssen, Johnson & Johnson, Italfármaco, Unolab, and Grupo Alter, among others. Additionally, he played a critical role in Nasdaq matters, acting as the responsible partner for Tigenix and as coordinator and advisor for PwC during VectiBio’s Nasdaq listing. With his extensive expertise in auditing and advising pharmaceutical and life sciences companies, Mr. Sánchez Quintana has been instrumental in supporting organizations through growth, regulatory, and financial milestones. Mr. Sánchez Quintana holds a bachelor’s degree in economics and business administration from the Complutense University of Madrid and a Master's in Economics and Business Management (Executive MBA) from IESE Business School (University of Navarra). Dr. Montserrat Vendrell is partner at Aliath bioventures, a Barcelona-based venture capital firm specializing in investments in life sciences companies. With a distinguished career spanning leadership roles in science and innovation, Dr. Vendrell previously served as CEO of Biocat (2007–2015), the Barcelona Science Park (2014–2015), and the Barcelona Institute of Science and Technology (BIST). Dr. Vendrell holds a Ph.D. in Biology from the University of Barcelona and conducted post-doctoral research at Hoffmann-La Roche in New Jersey, USA, as well as at the Spanish National Research Council (CSIC). She also earned a Master's in Scientific Communication from UPF-Barcelona School of Management and completed the General Management Program (PDG) at IESE Business School. In addition to her current role at Aliath bioventures, Dr. Vendrell serves as Chair of the Executive Committee of the Pasqual Maragall Foundation for Research in Alzheimer’s Disease, reflecting her ongoing dedication to advancing biomedical innovation and research. She is also Board-Director at the following Biotech companies: Peptomyc, Ona Therapeutics, Inbrain Neuroelectronics, and Accure Therapeutics.
